Platelets from diabetic subjects show diminished sensitivity to prostacyclin.
Prostacyclin, an unstable metabolite of arachidonic acid metabolism, has been shown to have potent platelet antiaggregatory and vasodilator activity. Available evidence suggests that arterial prostacyclin production is diminished in the diabetic state. In this study we have examined the sensitivity of platelets from diabetic subjects to the antiaggregatory effects of prostacyclin in vitro and report that platelets from some diabetic patients show diminished sensitivity to the antiaggregatory effects of prostacyclin. Thus diabetic subjects may not only have diminished prostacyclin production but also their platelets may be less sensitive to its effects. These findings may help to explain the increase in vascular disease observed in diabetic patients.
D000244:Adenosine Diphosphate / Q000494:pharmacology; D000293:Adolescent; D000328:Adult; D000368:Aged; D003864:Depression, Chemical; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000097:blood* / Q000145:classification; D003925:Diabetic Angiopathies / Q000097:blood / Q000150:complications; D011464:Epoprostenol / Q000494:pharmacology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects*; D011453:Prostaglandins / Q000494:pharmacology*
D011453:Prostaglandins; D000244:Adenosine Diphosphate; D011464:Epoprostenol